MedTrace Logo

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

NCT07493148 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-03-25

No results posted yet for this study

Summary

Efficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in elderly patients with newly diagnosed MYC/BCL2 double-expressor DLBCL.

Conditions

  • Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions

DRUG

Chidamide

Chidamide, oral, 20 mg (4 tablets) each time, twice a week, D1-14.

DRUG

Rituximab

Rituximab, 375 mg/m² IV, Cycle 1-4, Day 1.

DRUG

Cyclophosphamide

Cyclophosphamide, 400 mg/m² IV, Cycle 1-4, Day 2.

DRUG

Doxorubicin

Doxorubicin, 25 mg/m² IV, Cycle 1-4, Day 2.

DRUG

Vincristine

Vincristine, 1 mg/m² IV, Cycle 1-4, Day 2.

DRUG

Prednisone

Prednisone, 40 mg/m² orally, Cycle 1-4, Days 1-5.

DRUG

Chidamide + Rituximab maintenance

Chidamide, oral, 20 mg (4 tablets) each time, twice a week, D1-14. Rituximab, 375 mg/m² IV, once every 12 weeks. 21 days/cycle.

Sponsors & Collaborators

  • Ou Bai, MD/PHD

    lead OTHER

Principal Investigators

  • Ou Bai, PHD · The First Bethune Hospital of Jilin University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2029-12-30
Completion
2029-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07493148 on ClinicalTrials.gov